Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Disciplined Investing, especially the NAIC way -- Ignore unavailable to you. Want to Upgrade?

To: The Philosopher who wrote (328)	5/10/2002 4:15:34 PM
From: - with a K	Read Replies (1) \| Respond to of 469

Yes, it's not a classic NAIC stock. In fact, I said the SSG looks like teenage vomit in a mosh pit when I posted my notes in a value thread here. (I mistakenly thought I had posted it on the NAIC thread, but now you know why I didn't!) Sorry for not making that clear up front. In the value thread I also said about PRX: * (February 20, 2002) PRX got whacked 36% today because they announced a competitor got FDA approval for their weight gain drug for which PRX had a head start. (Bristol-Meyers makes the propriety drug that PRX first copied; now another generic is in the game.) My thesis for buying: * severe market overreaction (Even though the PRX generic accounted for up 25% of their business, they lost 36% of stock value in one day. * Seems like a great value at this price. Recent fundamentals are good. * It bounced off it's low and has shown some strength in a choppy market (well, at least until recently!) * With all the bad news from Bristol-Myers, Merck, Elan, and Watson, this is a contrarian play when things look bleakest for drug companies. * Fell dramatically below its 200 DMA and (should?) pull back up to around $25-28 BUT: Not a steady-eddy kind of company. Ugly chart. Lost money 1997-00; current liabilities are rising steadily.